4016.SR(4016.SR)
4016.SR
Middle East Pharmaceutical Industries Company (4016.SR) is a leading manufacturer of generic and branded pharmaceuticals in Saudi Arabia, with a strong focus on therapeutic areas such as cardiovascular, diabetes, and oncology. The company benefits from a robust distribution network across the GCC and has established partnerships with international pharmaceutical firms, enhancing its competitive position in the regional market.
The company generates revenue primarily through the sale of generic and branded pharmaceuticals, leveraging its strong R&D capabilities to develop cost-effective drugs. Its competitive advantages include a well-established distribution network, regulatory compliance expertise, and strategic partnerships that enhance product offerings.
Regulatory approvals for new drug formulations
Changes in healthcare policies affecting drug pricing
Fluctuations in raw material costs, particularly APIs
Market share gains in key therapeutic areas
Regulatory changes that could impact drug pricing and market access
Technological disruption in drug development processes
Increasing competition from local and international generic manufacturers
Potential entry of large multinational pharmaceutical companies into the GCC market
Low liquidity risk due to a strong current ratio of 2.85
Potential risks associated with currency fluctuations in international operations
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but demand can be influenced by overall healthcare spending trends.
The company has minimal exposure to interest rate fluctuations due to low debt levels (Debt/Equity of 0.20), which reduces financing costs and maintains valuation multiples.
minimal
growth - Investors may be drawn to the company's strong revenue growth and expansion potential in the GCC market.
moderate - The stock has experienced fluctuations, but its fundamentals provide a stabilizing effect.